IMTX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IM

Mkt Cap

$1.02B

Volume

824.11K

Next Earnings

November 16th

Loading chart

IM

IMTXImmatics N.V. Ordinary Shares

IMTX

Pay with—

Available Balance0.00

IM

Mkt Cap

$1.09B

Volume

824.11K

Next Earnings

November 16th

Chart Financials Earnings News About Insider Filings

Immatics Announces $150 Million Underwritten OfferingImmatics N.V. announced an underwritten public offering of 12.9 million ordinary shares at $8.69 per share and 4.3 million pre-funded warrants, raising approximately $150 million in gross proceeds. The offering is expected to close on August 26, 2026, with Jefferies, Leerink Partners, and Cantor serving as joint book-running managers.GlobeNewswire Inc. · Aug 25, 2026

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual MeetingImmatics announced extended Phase 1b data for anzu-cel (IMA203), a PRAME-directed TCR T-cell therapy, showing 56% confirmed objective response rate, 14.6 months median duration of response, and 16.2 months median overall survival in metastatic melanoma patients. The therapy demonstrated rapid, deep and durable anti-tumor activity with a manageable safety profile. The Phase 3 SUPRAME trial remains on track for BLA submission in H1 2027.GlobeNewswire Inc. · Jun 1, 2026

Synovial Sarcoma Clinical Trial Pipeline Accelerates as 15+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsightOver 15 pharmaceutical companies are actively developing more than 20 pipeline drugs for synovial sarcoma treatment, with promising therapies in various clinical trial stages. Key players including Takara Bio, Immatics, Moderna, Adaptimmune, and Zelluna are advancing innovative approaches such as TCR-T therapies and bispecific antibodies to address the significant unmet medical need in this rare cancer indication.GlobeNewswire Inc. · May 28, 2026

PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic NephroblastomaImmatics announced that a 17-year-old patient with advanced metastatic nephroblastoma achieved deep remission following treatment with a PRAME-directed TCR T-cell therapy. The patient, who had exhausted all available treatment options, experienced marked regression of liver, lung, and brain metastases with ongoing response at 6 months follow-up. The case will be presented at the AACR Annual Meeting 2026, supporting the therapeutic potential of PRAME TCR T-cell therapy in pediatric solid tumors.GlobeNewswire Inc. · Apr 17, 2026

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 CongressImmatics reported promising initial anti-tumor activity for its second-generation PRAME cell therapy IMA203CD8 in a Phase 1a dose escalation trial, showing encouraging clinical responses across multiple cancer types, particularly in ovarian carcinoma.GlobeNewswire Inc. · Dec 11, 2025

Immatics Announces $125 Million Underwritten OfferingImmatics N.V. plans to sell 12.5 million ordinary shares at $10.00 per share, expecting to raise $125 million in a public offering managed by Jefferies, Leerink Partners, and Cantor.GlobeNewswire Inc. · Dec 5, 2025

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development StepsImmatics reported promising Phase 1a clinical trial results for two bispecific cancer therapies, IMA402 and IMA401, demonstrating favorable tolerability and deep, durable responses in heavily pre-treated patients with solid tumors across multiple cancer types.GlobeNewswire Inc. · Nov 12, 2025

Immatics Appoints Venkat Ramanan as Chief Financial OfficerImmatics N.V. announced the appointment of Venkat Ramanan, Ph.D. as its new Chief Financial Officer, replacing Arnd Christ. Dr. Ramanan brings over 25 years of biopharmaceutical finance experience from companies like Seagen, Gilead Sciences, and Amgen.GlobeNewswire Inc. · Oct 1, 2025

TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsightThe T-cell receptor (TCR) therapy pipeline is rapidly expanding, with over 80 pharmaceutical companies actively developing more than 100 TCR therapies for various cancers, including solid tumors. Several promising pipeline candidates are in different stages of clinical trials, showcasing the potential of TCR therapy to revolutionize cancer treatment.GlobeNewswire Inc. · Mar 6, 2025

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAMEImmatics announced positive clinical data for its TCR-T therapy candidates targeting PRAME, a protein frequently expressed in solid cancers. The data showed deep and durable responses in heavily pretreated patients, supporting the advancement of these therapies into late-stage development.GlobeNewswire Inc. · Nov 8, 2024

to start trading

IM

IMTXImmatics N.V. Ordinary Shares

IMTX

Pay with—

Available Balance0.00

Your PositionYou don't own any IMTX yet.

Related Tickers

Earnings